Vivek Nimgaonkar News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Penn Medicine, Philadelphia: First Mutation-Targeted Bladder Cancer Drug May Be Under-Used | India Education | Latest Education News | Global Educational News

Penn Medicine, Philadelphia: First Mutation-Targeted Bladder Cancer Drug May Be Under-Used | India Education | Latest Education News | Global Educational News
indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.

United statesVivek nimgaonkarRonac mamtaniPenn centerUniversity of pennsylvaniaDrug administrationBiopsy laboratoryPerelman school of medicineAmerican cancer societyPerelman schoolErica carpenterLiquid biopsyFibroblast growth factor receptors

UPenn Researchers Find Low Uptake of Janssen s Balversa in Eligible Bladder Cancer Patients

While low FGFR biomarker testing rates may be contributing to the drug's slow adoption, the analysis found low uptake even among patients who did get tested.

Vivek nimgaonkarJanssen balversaQiagen therascreenRonac mamtaniPenn centerOhio state university comprehensive cancer center jamesTumor material laboratoryDrug administrationUniversity of pennsylvaniaFlatiron healthPrecision medicineErica carpenterCirculating tumor material laboratory

Penn study finds low uptake of first mutation-targeted bladder cancer drug

The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial, suggests a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.

United statesVivek nimgaonkarRonac mamtaniEmily hendersonPenn centerUniversity of pennsylvaniaDrug administrationBiopsy laboratoryPerelman school of medicineAmerican cancer societyPerelman schoolErica carpenterLiquid biopsyFibroblast growth factor receptorsBladder cancerCancer treatment